TW202214286A - 用於與血管新生抑制劑組合使用之抗t細胞抗原結合分子 - Google Patents

用於與血管新生抑制劑組合使用之抗t細胞抗原結合分子 Download PDF

Info

Publication number
TW202214286A
TW202214286A TW110122300A TW110122300A TW202214286A TW 202214286 A TW202214286 A TW 202214286A TW 110122300 A TW110122300 A TW 110122300A TW 110122300 A TW110122300 A TW 110122300A TW 202214286 A TW202214286 A TW 202214286A
Authority
TW
Taiwan
Prior art keywords
antigen
antibody
administration
pharmaceutical composition
binding molecule
Prior art date
Application number
TW110122300A
Other languages
English (en)
Chinese (zh)
Inventor
田中孝欣
佐野祐治
川合由美子
Original Assignee
日商中外製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 日商中外製藥股份有限公司 filed Critical 日商中外製藥股份有限公司
Publication of TW202214286A publication Critical patent/TW202214286A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/303—Liver or Pancreas
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
TW110122300A 2020-06-19 2021-06-18 用於與血管新生抑制劑組合使用之抗t細胞抗原結合分子 TW202214286A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2020-106501 2020-06-19
JP2020106501 2020-06-19

Publications (1)

Publication Number Publication Date
TW202214286A true TW202214286A (zh) 2022-04-16

Family

ID=79268097

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110122300A TW202214286A (zh) 2020-06-19 2021-06-18 用於與血管新生抑制劑組合使用之抗t細胞抗原結合分子

Country Status (15)

Country Link
US (1) US20230235056A1 (cg-RX-API-DMAC7.html)
EP (1) EP4186527A4 (cg-RX-API-DMAC7.html)
JP (2) JP7250219B2 (cg-RX-API-DMAC7.html)
KR (2) KR102594943B1 (cg-RX-API-DMAC7.html)
CN (1) CN115768478A (cg-RX-API-DMAC7.html)
AU (1) AU2021292932A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025536A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180951A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003622A1 (cg-RX-API-DMAC7.html)
CR (1) CR20230014A (cg-RX-API-DMAC7.html)
IL (1) IL299127A (cg-RX-API-DMAC7.html)
MX (1) MX2022015764A (cg-RX-API-DMAC7.html)
PE (1) PE20230435A1 (cg-RX-API-DMAC7.html)
TW (1) TW202214286A (cg-RX-API-DMAC7.html)
WO (1) WO2021256555A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
WO2025120867A1 (en) * 2023-12-08 2025-06-12 Astellas Pharma Inc. Combination therapy involving bispecific binding agents binding to cldn18.2 and cd3 and anti-vegfr2 antibodies
TW202539742A (zh) * 2024-02-08 2025-10-16 大陸商上海翰森生物醫藥科技有限公司 抗體藥物偶聯物和抗vegf抗體的聯合應用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773719A (en) 1966-12-06 1973-11-20 Hoffmann La Roche 2-aminoxy-2'-acyl-acetanilide
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2323757C (en) 1998-04-02 2011-08-02 Genentech, Inc. Antibody variants and fragments thereof
HUP0104865A3 (en) 1999-01-15 2004-07-28 Genentech Inc Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
EP2471816A1 (en) 2006-08-30 2012-07-04 Genentech, Inc. Multispecific antibodies
EP2144931A2 (en) 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
EP3663318A1 (en) 2008-01-07 2020-06-10 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
TWI736437B (zh) 2010-11-30 2021-08-11 日商中外製藥股份有限公司 細胞傷害誘導治療劑
MX380176B (es) 2014-04-07 2025-03-12 Chugai Pharmaceutical Co Ltd Molecula ligada a antigeno inmunoactivada.
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
EP3431102A4 (en) * 2016-03-14 2019-09-25 Chugai Seiyaku Kabushiki Kaisha CELL DAMAGING THERAPEUTIC MEDICAMENT FOR USE IN CANCER THERAPY
WO2018038046A1 (ja) 2016-08-22 2018-03-01 中外製薬株式会社 ヒトgpc3ポリペプチドを発現する遺伝子改変非ヒト動物
EP3541843A1 (en) * 2016-11-15 2019-09-25 Genentech, Inc. Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies
EP3600357A4 (en) * 2017-03-31 2021-01-06 The Board of Trustees of the Leland Stanford Junior University METHODS OF TREATING T-LYMPHOCYTE DEPLETION BY INHIBITING OR MODULATING T-LYMPHOCYTE RECEPTOR SIGNALING

Also Published As

Publication number Publication date
EP4186527A1 (en) 2023-05-31
JP2023078311A (ja) 2023-06-06
JP7250219B2 (ja) 2023-03-31
KR20230028225A (ko) 2023-02-28
KR20230152789A (ko) 2023-11-03
PE20230435A1 (es) 2023-03-08
CR20230014A (es) 2023-02-17
WO2021256555A1 (ja) 2021-12-23
CN115768478A (zh) 2023-03-07
CL2022003622A1 (es) 2023-06-23
US20230235056A1 (en) 2023-07-27
BR112022025536A2 (pt) 2023-01-17
IL299127A (en) 2023-02-01
JPWO2021256555A1 (cg-RX-API-DMAC7.html) 2021-12-23
KR102594943B1 (ko) 2023-10-27
MX2022015764A (es) 2023-01-19
CA3180951A1 (en) 2021-12-23
EP4186527A4 (en) 2024-07-17
AU2021292932A1 (en) 2023-01-05

Similar Documents

Publication Publication Date Title
JP7854529B2 (ja) 抗nkg2a抗体およびその使用
KR102962557B1 (ko) 새로운 il-15 프로드럭 및 이를 사용하는 방법
CN110536903B (zh) 抗ox40抗体及其用途
JP7118073B2 (ja) 抗tim-3抗体を用いてがんを処置する方法
JP2022065073A (ja) Bcma結合分子及びその使用方法
JP2021008487A (ja) 抗nkg2a抗体を使用した治療計画
TWI868154B (zh) 用於與細胞激素抑制劑組合使用之抗t細胞抗原結合分子
CN114728065A (zh) 针对cd3和bcma的抗体和自其制备的双特异性结合蛋白
CN104024276A (zh) Lsr抗体及其用于癌症治疗的用途
JP2017523771A (ja) グルココルチコイド誘導腫瘍壊死因子受容体(gitr)に対する抗体およびその使用
JP2023078311A (ja) 血管新生阻害剤と組み合わせて使用するための抗t細胞抗原結合分子
JP2022512905A (ja) 新規アンタゴニスト抗tnfr2抗体分子
TW202319400A (zh) 用於治療aml之抗體
WO2022117572A2 (en) An ltbr agonist in combination therapy against cancer
JP2023536631A (ja) 多重特異性結合性作用剤およびその使用
JP2023504531A (ja) 腫瘍治療のための二重特異性融合タンパク質と抗Her2抗体の組合せ
KR20220035150A (ko) 특정 환자에서 암의 치료를 위한 항체 조합물
JP2025534285A (ja) プロテアーゼ活性化ポリペプチド
WO2019242619A1 (zh) 全人源的抗lag-3抗体及其应用
JP2022554374A (ja) 抗tigit抗体及びその使用
JP2023554422A (ja) がんの治療のための多重特異性抗体
CN115244084A (zh) 抗gitr抗体及其用途
TW202423987A (zh) 抗ccr8抗體及其應用
HK40082394A (en) Anti-t cell antigen-binding molecule for use in combination with angiogenesis inhibitor
CN115485302A (zh) 具有增强的激动剂活性的针对cd40的抗体